Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Initiates a Phase 2b Confirmatory Dose-Ranging Trial With Lead Compound FX006
Multi-Center Trial Will Enroll Approximately 300 Patients in the U.S. for the Treatment of Pain Associated With Osteoarthritis (OA) of the Knee
View HTML
Toggle Summary Flexion Therapeutics to Present at the 13th Annual Needham Healthcare Conference View HTML
Toggle Summary Flexion Reports Year-End 2013 Financial Results View HTML
Toggle Summary Flexion Therapeutics to Report Year-End 2013 Earning Results on March 27, 2014 View HTML
Toggle Summary Flexion Therapeutics to Present at the 34th Annual Cowen Health Care Conference View HTML
Toggle Summary Flexion Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares View HTML
Toggle Summary Flexion Therapeutics Announces Pricing of Initial Public Offering View HTML
Toggle Summary Flexion Therapeutics Files Registration Statement for Proposed Initial Public Offering View HTML
Toggle Summary Flexion Therapeutics Presents Robust Phase 2b Data for FX006 at 2013 American College of Rheumatology Annual Scientific Meeting
– In a clinical trial, a single-dose of 40 mg of FX006 demonstrated enhanced therapeutic effects relative to the approved injectable dose of commonly available, immediate release steroid in patients with osteoarthritis of the knee –
View HTML
Toggle Summary Flexion Therapeutics to Present Phase 2b Data for FX006 at 2013 American College of Rheumatology Annual Scientific Meeting
– Oral presentation at ACR will highlight results from first head-to-head dose-ranging study comparing FX006 with approved injectable dose of commonly prescribed, immediate release steroid for patients with osteoarthritis (OA) of the knee –
View HTML